Literature DB >> 23415932

Active immunotherapy for chronic diseases.

Martin F Bachmann1, Piers Whitehead.   

Abstract

With the effective control of infectious diseases in many parts of the world, chronic, non-communicable diseases have become the major cause of death and disability. Monoclonal antibodies (mAbs) have become an important class of drugs for the treatment of such diseases. Nevertheless, mAbs suffer from major shortcomings in a chronic setting: most notably, generation of anti-antibodies and high cost of goods. Here, we discuss a novel approach to treat chronic diseases based on active rather than passive immunization and contrast the 2 treatment modalities to highlight their respective advantages and disadvantages. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23415932     DOI: 10.1016/j.vaccine.2013.02.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

Review 2.  Raising expectations for subunit vaccine.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2014-11-24       Impact factor: 5.226

3.  Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis.

Authors:  Fernando Civeira; Estíbaliz Jarauta
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

4.  A cholesterol-lowering VLP vaccine that targets PCSK9.

Authors:  Erin Crossey; Marcelo J A Amar; Maureen Sampson; Julianne Peabody; John T Schiller; Bryce Chackerian; Alan T Remaley
Journal:  Vaccine       Date:  2015-09-26       Impact factor: 3.641

5.  A clinically applicable adjuvant for an atherosclerosis vaccine in mice.

Authors:  Kouji Kobiyama; Melanie Vassallo; Jessica Mitzi; Holger Winkels; Hong Pei; Takayuki Kimura; Jacqueline Miller; Dennis Wolf; Klaus Ley
Journal:  Eur J Immunol       Date:  2018-08-12       Impact factor: 5.532

6.  δ-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation.

Authors:  Fei Huang; Junying Chen; Ruilong Lan; Zeng Wang; Ruiqing Chen; Jingan Lin; Lurong Zhang; Lengxi Fu
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

7.  LTB-Syn: a recombinant immunogen for the development of plant-made vaccines against synucleinopathies.

Authors:  Jaime I Arevalo-Villalobos; Dania O Govea-Alonso; Elizabeth Monreal-Escalante; Sergio Zarazúa; Sergio Rosales-Mendoza
Journal:  Planta       Date:  2017-03-17       Impact factor: 4.116

8.  Peptide-based vaccination against OPN integrin binding sites does not improve cardio-metabolic disease in mice.

Authors:  Nicole G Grün; Karin Strohmeier; Veronica Moreno-Viedma; Marie Le Bras; Christine Landlinger; Karina Zeyda; Bettina Wanko; Lukas Leitner; Günther Staffler; Maximilian Zeyda; Thomas M Stulnig
Journal:  Immunol Lett       Date:  2016-09-14       Impact factor: 3.685

9.  Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.

Authors:  Mohey Eldin El Shikh; Maciej Kmieciak; Masoud H Manjili; Andras K Szakal; Costantino Pitzalis; John G Tew
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

Review 10.  Why HIV virions have low numbers of envelope spikes: implications for vaccine development.

Authors:  John Schiller; Bryce Chackerian
Journal:  PLoS Pathog       Date:  2014-08-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.